Chengdu Brilliant Pharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- BT-KTM-I · Cardiovascular
BT-KTM-I is a small molecule that targets the PDE3 enzyme. - Ketanest®S · Anesthesiology
Ketanest®S is a rapid-acting anesthetic that blocks NMDA receptors in the central nervous system to produce dissociative anesthesia and analgesia.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: